Literature DB >> 24682909

Relationship between lower urinary tract symptoms and metabolic syndrome in a Chinese male population.

J G Pan1, M Liu, X Zhou.   

Abstract

OBJECTIVES: To investigate whether the metabolic syndrome (MetS) is a risk factor for lower urinary tract symptoms (LUTS), as defined by the International Prostate Symptom Score in a Chinese male population with benign prostate hyperplasia (BPH).
METHODS: We retrospectively analyzed the clinical data obtained from 1,052 Chinese men with BPH. Serum levels of prostate specific antigen, fasting blood glucose (FBG), high-density lipoprotein cholesterol, total cholesterol and triglyceride were determined and recorded. Multiple logistic regression statistical analysis was used to investigate the degree of the association between LUTS and MetS.
RESULTS: Of the 1,052 enrolled patients, 648 (61.60 %) had moderate LUTS and 404 (38.40 %) had severe LUTS. A multiple logistic regression analysis showed that age (OR 2.02, 95 % CI 1.04-4.63), FBG (OR 3.65, 95 % CI 1.68-7.98) and presence of MetS (OR 3.64, 95 % CI 1.24-6.14) were significant predictors of severe LUTS.
CONCLUSIONS: The results of our study suggest that MetS is associated with an increase risk of total volume and annual growth rate of prostate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682909     DOI: 10.1007/s40618-013-0018-9

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

Review 2.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

Review 3.  Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis.

Authors:  L Landsberg
Journal:  Q J Med       Date:  1986-12

4.  Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancer prostate surgery in U.S. men.

Authors:  Elizabeth A Platz; Ellen Smit; Gary C Curhan; Leroy M Nyberg; Edward Giovannucci
Journal:  Urology       Date:  2002-06       Impact factor: 2.649

5.  Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.

Authors:  Debra E Irwin; Zoe S Kopp; Barnabie Agatep; Ian Milsom; Paul Abrams
Journal:  BJU Int       Date:  2011-01-13       Impact factor: 5.588

6.  Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

Authors:  J Hammarsten; B Högstedt
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

7.  Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey.

Authors:  Varant Kupelian; Kevin T McVary; Steven A Kaplan; Susan A Hall; Carol L Link; Lalitha Padmanabhan Aiyer; Patrick Mollon; Nihad Tamimi; Raymond C Rosen; John B McKinlay
Journal:  J Urol       Date:  2009-06-18       Impact factor: 7.450

8.  Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population.

Authors:  Hyoung Keun Park; Hae Won Lee; Kwang Soo Lee; Seok-Soo Byun; Sung Jin Jeong; Sung Kyu Hong; Sang Eun Lee; Joon Hyuk Park; Seok Bum Lee; Ki Woong Kim
Journal:  Urology       Date:  2008-07-02       Impact factor: 2.649

9.  The development of human benign prostatic hyperplasia with age.

Authors:  S J Berry; D S Coffey; P C Walsh; L L Ewing
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

10.  Relationship between metabolic syndrome and prostate volume in Korean men under 50 years of age.

Authors:  Sung Jin Yim; Young Sam Cho; Kwan Joong Joo
Journal:  Korean J Urol       Date:  2011-06-17
View more
  6 in total

1.  The Effect of Different Metabolic Syndrome: Definitions on the Relationship Between Metabolic Syndrome and LUTS in Men With Benign Prostatic Enlargement.

Authors:  Orhan Ünal Zorba; Hakkı Uzun; Görkem Akça; Selim Yazar
Journal:  Am J Mens Health       Date:  2016-06-23

2.  Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

Authors:  G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-04-01       Impact factor: 4.256

Review 3.  The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

Authors:  Jian-Ye Wang; Yan-Yan Fu; De-Ying Kang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

4.  The association between metabolic syndrome and lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males: evidence based on propensity score matching.

Authors:  Yang Xiong; Yangchang Zhang; Jun Tan; Feng Qin; Jiuhong Yuan
Journal:  Transl Androl Urol       Date:  2021-01

5.  Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.

Authors:  Asma Omran; Bianca M Leca; Eduard Oštarijaš; Natasha Graham; Ana Sofia Da Silva; Zoulikha M Zaïr; Alexander D Miras; Carel W le Roux; Royce P Vincent; Linda Cardozo; Georgios K Dimitriadis
Journal:  Ther Adv Endocrinol Metab       Date:  2021-12-08       Impact factor: 3.565

6.  Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.

Authors:  Jee Soo Park; Kyo Chul Koo; Hye Kyung Kim; Byung Ha Chung; Kwang Suk Lee
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.